Clinical efficacy of IMRT radiotherapy combined with EGFR-TKI in the targeting therapy of advanced non-small cell lung cancer with EGFR mutation

ObjectiveTo investigate the clinical effects of intensity modulated radiation therapy(IMRT) combined with epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) in the targeting therapy of advanced non-small cell lung cancer with epidermal growth factor receptor(EGFR) mutation.

MethodsThe clinical data of 56 patients with EGFR mutated advanced non-small cell lung cancer were retrospectively analyzed, and the patients were divided into the combination group and contorl group according to the treatment method(28 cases in each group).The control group was treated with EGFR-TKI, and the combination group was treated with IMRT on the basis of the control group.The efficacy and survival between two groups were compared, and the incidence rate of adverse reactions during treatment were counted.

ResultsAfter treatment, the objective remission rate in the combination group was 82.14%, which was significantly higher than that in control group(57.14%)(P < 0.01).The median progression free survival and median overall survival in combination group were significantly longer than those in control group(P < 0.05).The differences of the incidence rates of the gastrointestinal reaction, myelosuppression, liver and kidney function damage, skin reaction, dizziness, headache and oral mucositis were not statistically significant between two groups(P>0.05).

ConclusionsThe IMRT combined with EGFR-TKI in the targeting treatment of EGFR mutated advanced non-small cell lung cancer is effective, which can improve the objective remission rate and survival of patients, and do not increase the incidence rate of adverse reactions.